HRP20220692T1 - Brzodjelujući pripravci inzulina - Google Patents
Brzodjelujući pripravci inzulina Download PDFInfo
- Publication number
- HRP20220692T1 HRP20220692T1 HRP20220692TT HRP20220692T HRP20220692T1 HR P20220692 T1 HRP20220692 T1 HR P20220692T1 HR P20220692T T HRP20220692T T HR P20220692TT HR P20220692 T HRP20220692 T HR P20220692T HR P20220692 T1 HRP20220692 T1 HR P20220692T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- concentration
- insulin
- pharmaceutical
- preparation according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 2
- 229940123452 Rapid-acting insulin Drugs 0.000 title 1
- 108010026951 Short-Acting Insulin Proteins 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 10
- 102000004877 Insulin Human genes 0.000 claims 5
- 108090001061 Insulin Proteins 0.000 claims 5
- 229940125396 insulin Drugs 0.000 claims 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims 3
- 229940100630 metacresol Drugs 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 239000003755 preservative agent Substances 0.000 claims 3
- 230000002335 preservative effect Effects 0.000 claims 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 230000001256 tonic effect Effects 0.000 claims 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- 108010065920 Insulin Lispro Proteins 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 229940090047 auto-injector Drugs 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 229960002068 insulin lispro Drugs 0.000 claims 1
- 229910001629 magnesium chloride Inorganic materials 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 238000005086 pumping Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (17)
1. Farmaceutski pripravak, naznačen time što sadrži:
a. inzulin, u koncentraciji od otprilike 100 do otprilike 200 MJ/ml;
b. citrat, u koncentraciji od otprilike 15 do otprilike 35 mM;
c. cink, u koncentraciji od otprilike 0,3 do otprilike 0,8 mM; i
d. konzervans; i
gdje pripravak ne sadrži EDTA ili bilo koji oligosaharid.
2. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što dodatno sadrži magnezijev klorid u koncentraciji do otprilike 5 mM.
3. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što je inzulin inzulin lispro.
4. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što je koncentracija citrata od otprilike 15 do otprilike 25 mM.
5. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što se konzervans bira između fenola ili meta-krezola.
6. Farmaceutski pripravak u skladu s patentnim zahtjevom 5, naznačen time što konzervans je meta-krezol.
7. Farmaceutski pripravak u skladu s patentnim zahtjevom 6, naznačen time što je koncentracija meta-krezola od otprilike 2,5 do otprilike 3,8 mg/ml.
8. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što dodatno sadrži sredstvo za toničnost.
9. Farmaceutski pripravak u skladu s patentnim zahtjevom 8, naznačen time što je sredstvo za toničnost glicerol.
10. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što je pH pripravka od otprilike 7,0 do otprilike 7,8.
11. Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što pripravak osigurava unos inzulina u krv koji je najmanje 20% brži nego za pripravke koji sadrže isti inzulin no koji ne sadrže citrat.
12. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što je namijenjen upotrebi u terapiji.
13. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što je namijenjen upotrebi u liječenju dijabetesa.
14. Proizvodni artikl, naznačen time što sadrži bilo koji od farmaceutskih pripravaka u skladu s patentnim zahtjevima 1 do 11.
15. Proizvodni artikl u skladu s patentnim zahtjevom 14, naznačen time što je bočica za višekratnu upotrebu.
16. Proizvodni artikl u skladu s patentnim zahtjevom 14, naznačen time što je autoinjektor za višekratnu upotrebu.
17. Proizvodni artikl u skladu s patentnim zahtjevom 14, naznačen time što je crpni uređaj za terapiju kontinuiranom supkutanom infuzijom inzulina.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462092407P | 2014-12-16 | 2014-12-16 | |
| EP15817678.4A EP3233108B1 (en) | 2014-12-16 | 2015-12-09 | Rapid-acting insulin compositions |
| PCT/US2015/064744 WO2016100042A1 (en) | 2014-12-16 | 2015-12-09 | Rapid-acting insulin compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220692T1 true HRP20220692T1 (hr) | 2022-07-08 |
Family
ID=55066806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220692TT HRP20220692T1 (hr) | 2014-12-16 | 2015-12-09 | Brzodjelujući pripravci inzulina |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US9993555B2 (hr) |
| EP (2) | EP4108253A1 (hr) |
| JP (4) | JP6328855B2 (hr) |
| AR (1) | AR102869A1 (hr) |
| DK (1) | DK3233108T3 (hr) |
| ES (1) | ES2911207T3 (hr) |
| HR (1) | HRP20220692T1 (hr) |
| HU (1) | HUE058764T2 (hr) |
| LT (1) | LT3233108T (hr) |
| MA (1) | MA41188B1 (hr) |
| MD (1) | MD3233108T2 (hr) |
| PL (1) | PL3233108T3 (hr) |
| PT (1) | PT3233108T (hr) |
| RS (1) | RS63174B1 (hr) |
| SI (1) | SI3233108T1 (hr) |
| TW (1) | TW201630622A (hr) |
| WO (1) | WO2016100042A1 (hr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102037008B (zh) | 2008-03-18 | 2016-08-31 | 诺沃-诺迪斯克有限公司 | 蛋白酶稳定化的、酰化胰岛素类似物 |
| AU2013346624B2 (en) | 2012-11-13 | 2018-08-09 | Adocia | Quick-acting insulin formulation including a substituted anionic compound |
| AR102869A1 (es) | 2014-12-16 | 2017-03-29 | Lilly Co Eli | Composiciones de insulina de rápida acción |
| JO3749B1 (ar) | 2015-08-27 | 2021-01-31 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
| GB201607918D0 (en) | 2016-05-06 | 2016-06-22 | Arecor Ltd | Novel formulations |
| EP3518893A1 (en) | 2016-09-29 | 2019-08-07 | Arecor Limited | Novel formulations |
| HUE060149T2 (hu) | 2016-12-16 | 2023-02-28 | Novo Nordisk As | Inzulint tartalmazó gyógyászati készítmények |
| US20180236080A1 (en) * | 2017-02-22 | 2018-08-23 | Adocia | Fast-acting insulin composition comprising a citric acid salt |
| EP3600233A4 (en) * | 2017-03-26 | 2020-10-21 | Stafford, Vivi, Robyn | METHOD OF TREATMENT OF SKIN DISEASES OF THE EYELIDS |
| ES2912162T3 (es) | 2017-06-01 | 2022-05-24 | Lilly Co Eli | Composiciones de insulina de acción rápida |
| WO2019193351A1 (en) | 2018-04-04 | 2019-10-10 | Arecor Limited | Medical infusion pump system for the delivery of an insulin compound |
| CA3094304A1 (en) | 2018-04-04 | 2019-10-10 | Arecor Limited | Medical infusion pump system for the delivery of an insulin compound |
| CA3094237A1 (en) | 2018-04-04 | 2019-10-10 | Arecor Limited | Medical infusion pump system for the delivery of an insulin compound |
| FR3083985A1 (fr) | 2018-07-23 | 2020-01-24 | Adocia | Dispositif pour injecter une solution d'insuline(s) |
| WO2019243627A1 (fr) | 2018-06-23 | 2019-12-26 | Adocia | Dispositif pour injecter une solution d'insuline(s) |
| AU2020235643A1 (en) * | 2019-03-14 | 2021-09-30 | Augusta University Research Institute, Inc. | Methods and compositions for supporting renal health |
| US10639328B1 (en) * | 2019-03-27 | 2020-05-05 | College Of William & Mary | Compositions and methods for reducing hyperglycemia and treating diabetes |
| US10799564B1 (en) | 2019-05-06 | 2020-10-13 | Baxter International Inc. | Insulin premix formulation and product, methods of preparing same, and methods of using same |
| WO2021055505A2 (en) * | 2019-09-17 | 2021-03-25 | Cass Pharmaceuticals, Inc. | Subcutaneously injectable insulin and glucagon formulations and methods of administration |
| US11951186B2 (en) | 2019-10-25 | 2024-04-09 | Willow Laboratories, Inc. | Indicator compounds, devices comprising indicator compounds, and methods of making and using the same |
| GB202004814D0 (en) | 2020-04-01 | 2020-05-13 | Arecor Ltd | Novel formulations |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK116527B (da) | 1967-03-01 | 1970-01-19 | Nordisk Insulinlab | Fremgangsmåde til fremstilling af en hurtigtvirkende, holdbar, neutral opløsning af rent krystallinsk okseinsulin eller okseinsulin, der ved tilsætning af Zn er krystalliserbart i vand, eller blandinger af okseinsulin og insulin af anden oprindelse. |
| DE3064888D1 (en) | 1979-04-30 | 1983-10-27 | Hoechst Ag | Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization |
| FI78616C (fi) | 1982-02-05 | 1989-09-11 | Novo Industri As | Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt. |
| US4839341A (en) * | 1984-05-29 | 1989-06-13 | Eli Lilly And Company | Stabilized insulin formulations |
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| NO162160C (no) | 1987-01-09 | 1989-11-15 | Medi Cult As | Serumfritt vekstmedium, samt anvendelse derav. |
| AU612141B2 (en) | 1987-02-25 | 1991-07-04 | Novo Nordisk A/S | Novel insulin derivatives |
| AU641631B2 (en) | 1988-12-23 | 1993-09-30 | Novo Nordisk A/S | Human insulin analogues |
| US5716927A (en) | 1988-12-23 | 1998-02-10 | Novo Nordisk A/S | Insulin analogs having a modified B-chain |
| US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
| US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
| US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
| US5866538A (en) | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
| AUPO066096A0 (en) | 1996-06-26 | 1996-07-18 | Peptide Delivery Systems Pty Ltd | Oral delivery of peptides |
| WO1999034821A1 (en) | 1998-01-09 | 1999-07-15 | Novo Nordisk A/S | Stabilised insulin compositions |
| ATE220917T1 (de) | 1999-01-26 | 2002-08-15 | Lilly Co Eli | Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten |
| AU779798C (en) | 1999-11-15 | 2005-11-17 | Hanamaraddi T. Gangal | Dextrose and insulin fluid formulation for intravenous infusion |
| JP4147234B2 (ja) | 2004-09-27 | 2008-09-10 | キヤノン株式会社 | 吐出用液体、吐出方法、カートリッジ及び吐出装置 |
| US20020141946A1 (en) | 2000-12-29 | 2002-10-03 | Advanced Inhalation Research, Inc. | Particles for inhalation having rapid release properties |
| DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
| EP1684793B1 (en) * | 2003-11-13 | 2011-09-21 | Novo Nordisk A/S | Pharmaceutical composition comprising an insulinotropic glp-1(7-37) analogue, asp(b28)-insulin, and a surfactant |
| ES2398838T3 (es) | 2004-03-12 | 2013-03-22 | Biodel, Inc. | Composiciones de suministro de fármacos de acción rápida |
| US20080090753A1 (en) | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
| US7713929B2 (en) * | 2006-04-12 | 2010-05-11 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| US20070086952A1 (en) | 2005-09-29 | 2007-04-19 | Biodel, Inc. | Rapid Acting and Prolonged Acting Inhalable Insulin Preparations |
| US8084420B2 (en) | 2005-09-29 | 2011-12-27 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| JP2009533471A (ja) | 2006-04-12 | 2009-09-17 | バイオデル， インコーポレイテッド | 即効型および長時間作用型組合せインスリン製剤 |
| US8084022B2 (en) | 2006-06-23 | 2011-12-27 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| WO2008013955A2 (en) | 2006-07-27 | 2008-01-31 | Nektar Therapeutics | Sustained release formulations for pulmonary delivery |
| ES2744384T3 (es) | 2007-06-13 | 2020-02-24 | Novo Nordisk As | Formulación farmacéutica que comprende un derivado de insulina |
| EP2036539A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Stable formulations of amylin and its analogues |
| TWI394580B (zh) | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
| US9060927B2 (en) * | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
| US20120094902A1 (en) | 2009-03-27 | 2012-04-19 | Adocia | Fast-acting insulin formulation |
| FR2943538B1 (fr) | 2009-03-27 | 2011-05-20 | Adocia | Formulation a action rapide d'insuline recombinante humaine |
| EP2612677B1 (en) | 2009-06-26 | 2015-05-06 | Novo Nordisk A/S | Preparation comprising insulin, nicotinamide and arginine |
| US20120178675A1 (en) | 2010-07-07 | 2012-07-12 | Biodel Inc. | Compositions And Methods For Modulating The Pharmacokinetics and Pharmacodynamics of Insulin |
| CA2839511C (en) * | 2011-06-17 | 2018-07-31 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
| US20130011378A1 (en) | 2011-06-17 | 2013-01-10 | Tzung-Horng Yang | Stable formulations of a hyaluronan-degrading enzyme |
| CN103889443A (zh) | 2011-06-17 | 2014-06-25 | 哈洛齐梅公司 | 使用透明质酸降解酶的持续皮下胰岛素输注法 |
| US20130231281A1 (en) | 2011-11-02 | 2013-09-05 | Adocia | Rapid acting insulin formulation comprising an oligosaccharide |
| WO2013102144A2 (en) | 2011-12-30 | 2013-07-04 | Halozyme, Inc. | Ph20 polypeptede variants, formulations and uses thereof |
| US9399065B2 (en) | 2012-04-16 | 2016-07-26 | Biodel Inc. | Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin |
| US9381247B2 (en) | 2012-04-16 | 2016-07-05 | Biodel Inc. | Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain |
| US20150174209A1 (en) | 2012-05-25 | 2015-06-25 | Amylin Pharmaceuticals. Llc | Insulin-pramlintide compositions and methods for making and using them |
| AU2013346624B2 (en) * | 2012-11-13 | 2018-08-09 | Adocia | Quick-acting insulin formulation including a substituted anionic compound |
| WO2015031709A1 (en) | 2013-08-30 | 2015-03-05 | Perosphere, Inc. | Rapid acting injectable formulations comprising a peptide and a vasodilatory agent |
| AU2015204491B2 (en) | 2014-01-13 | 2021-01-07 | Thermalin Inc. | Rapid action insulin formulations and pharmaceutical delivery systems |
| US20150273022A1 (en) | 2014-02-10 | 2015-10-01 | Biodel Inc. | Stabilized ultra-rapid-acting insulin formulations |
| US9795678B2 (en) | 2014-05-14 | 2017-10-24 | Adocia | Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound |
| AR102869A1 (es) * | 2014-12-16 | 2017-03-29 | Lilly Co Eli | Composiciones de insulina de rápida acción |
| JO3749B1 (ar) * | 2015-08-27 | 2021-01-31 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
-
2015
- 2015-12-01 AR ARP150103921A patent/AR102869A1/es unknown
- 2015-12-01 TW TW104140209A patent/TW201630622A/zh unknown
- 2015-12-09 JP JP2017531725A patent/JP6328855B2/ja active Active
- 2015-12-09 PL PL15817678T patent/PL3233108T3/pl unknown
- 2015-12-09 MD MDE20170200T patent/MD3233108T2/ro unknown
- 2015-12-09 HU HUE15817678A patent/HUE058764T2/hu unknown
- 2015-12-09 HR HRP20220692TT patent/HRP20220692T1/hr unknown
- 2015-12-09 SI SI201531823T patent/SI3233108T1/sl unknown
- 2015-12-09 ES ES15817678T patent/ES2911207T3/es active Active
- 2015-12-09 RS RS20220416A patent/RS63174B1/sr unknown
- 2015-12-09 DK DK15817678.4T patent/DK3233108T3/da active
- 2015-12-09 EP EP22164140.0A patent/EP4108253A1/en active Pending
- 2015-12-09 LT LTEPPCT/US2015/064744T patent/LT3233108T/lt unknown
- 2015-12-09 PT PT158176784T patent/PT3233108T/pt unknown
- 2015-12-09 MA MA41188A patent/MA41188B1/fr unknown
- 2015-12-09 EP EP15817678.4A patent/EP3233108B1/en active Active
- 2015-12-09 WO PCT/US2015/064744 patent/WO2016100042A1/en active Application Filing
- 2015-12-09 US US14/963,279 patent/US9993555B2/en active Active
-
2018
- 2018-04-18 JP JP2018079985A patent/JP7093669B2/ja active Active
- 2018-05-14 US US15/978,329 patent/US11123406B2/en active Active
-
2020
- 2020-12-24 JP JP2020214703A patent/JP7159277B2/ja active Active
-
2021
- 2021-09-17 US US17/478,747 patent/US11872266B2/en active Active
-
2022
- 2022-10-12 JP JP2022163910A patent/JP2023011641A/ja active Pending
-
2023
- 2023-12-14 US US18/540,193 patent/US20240238382A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220072105A1 (en) | 2022-03-10 |
| LT3233108T (lt) | 2022-05-10 |
| JP2023011641A (ja) | 2023-01-24 |
| JP6328855B2 (ja) | 2018-05-23 |
| US20190231851A1 (en) | 2019-08-01 |
| HUE058764T2 (hu) | 2022-09-28 |
| JP7093669B2 (ja) | 2022-06-30 |
| MA41188A (fr) | 2017-10-24 |
| US11872266B2 (en) | 2024-01-16 |
| DK3233108T3 (da) | 2022-04-11 |
| SI3233108T1 (sl) | 2022-05-31 |
| RS63174B1 (sr) | 2022-05-31 |
| ES2911207T3 (es) | 2022-05-18 |
| US9993555B2 (en) | 2018-06-12 |
| JP2021073187A (ja) | 2021-05-13 |
| TW201630622A (zh) | 2016-09-01 |
| MA41188B1 (fr) | 2022-08-31 |
| JP2018500314A (ja) | 2018-01-11 |
| EP3233108A1 (en) | 2017-10-25 |
| WO2016100042A1 (en) | 2016-06-23 |
| US11123406B2 (en) | 2021-09-21 |
| EP4108253A1 (en) | 2022-12-28 |
| JP2018138578A (ja) | 2018-09-06 |
| AR102869A1 (es) | 2017-03-29 |
| US20240238382A1 (en) | 2024-07-18 |
| PL3233108T3 (pl) | 2022-06-20 |
| PT3233108T (pt) | 2022-05-05 |
| JP7159277B2 (ja) | 2022-10-24 |
| EP3233108B1 (en) | 2022-03-30 |
| US20160166695A1 (en) | 2016-06-16 |
| MD3233108T2 (ro) | 2022-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220692T1 (hr) | Brzodjelujući pripravci inzulina | |
| HRP20211415T1 (hr) | Brzodjelujući pripravci inzulina | |
| ZA202102906B (en) | Liquid protein formulations containing viscosity-lowering agents | |
| HRP20221367T1 (hr) | Brzodjelujući inzulinski pripravci | |
| WO2016042163A3 (en) | Ophthalmic drug compositions | |
| MX344727B (es) | Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas. | |
| UA117103C2 (uk) | Сполука, яка має активність агоніста глюкагону | |
| JP2016539921A5 (hr) | ||
| AR090491A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo | |
| HRP20200704T1 (hr) | Vodena formulacija koja sadrži paracetamol i ibuprofen | |
| EA201791333A1 (ru) | Производные глюкагона с улучшенной стабильностью | |
| WO2015128403A3 (en) | An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue | |
| WO2015105981A3 (en) | Nutritional composition comprising hmb for increasing or maintaining lean body mass in subjects having reduced leucine to hmb conversion efficiency or undergoing diabetic treatment | |
| PE20171622A1 (es) | Formulacion de relacion fija de insulina glargina/lixisenatida | |
| BR112016024020A8 (pt) | composição farmacêutica | |
| JP2017502074A5 (hr) | ||
| WO2016100949A3 (en) | Method and compositions for dissolving or solubilizing therapeutic agents | |
| PH12018501274A1 (en) | Stabilized pharmaceutical composition containing pemetrexed or pharmaceutically acceptable salt thereof | |
| MX2017000878A (es) | Peptidos marinos y nucleotidos de pescado, composiciones y sus usos para reducir la glucosa en la sangre. | |
| PH12017501005A1 (en) | Injectable formulations of paracetamol | |
| EA201691206A1 (ru) | Ноотропное средство "пантокальцин" в жидкой форме | |
| PL414785A1 (pl) | Kwas 3-dodecylosulfanylomasłowy do zastosowania jako lek, zwłaszcza do zapobiegania rozwojowi insulinooporności oraz kompozycja farmaceutyczna zawierająca kwas 3-dodecylosulfanylomasłowy jako substancję czynną | |
| IuM et al. | Experience of Vasonat usage in treatment of patients with chronic toxic hepatitis | |
| TH172399A (th) | การบำบัดโรคเบาหวานด้วยสูตรผสมอินซูลินที่ออกฤทธิ์นาน | |
| UA102651U (uk) | Спосіб корекції ферментної системи антиоксидантного захисту організму глибокотільних корів за ендотоксикозу |